A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth … [Read more...] about A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
OXOART2, selected as one of the most exciting pieces of research presented at ESHRE 40th annual meeting celebrated in Amsterdam
Novel treatment improves embryo implantation and live birth rates in infertile women undergoing IVF and ICSI New … [Read more...] about OXOART2, selected as one of the most exciting pieces of research presented at ESHRE 40th annual meeting celebrated in Amsterdam
Oxolife will present the first OXO-001 results at the European Congress of Human Reproduction (ESHRE)
OXOLIFE is thrilled to announce that on Monday, July the 8th, our CEO, Agnès Arbat Arbat, will be presenting the … [Read more...] about Oxolife will present the first OXO-001 results at the European Congress of Human Reproduction (ESHRE)
OXO-001, for embryo implantation makes headlines in the Daily News!
Oxolife and its phase II asset OXO-001 for embryo implantation have been featured in the UK's highest circulated daily … [Read more...] about OXO-001, for embryo implantation makes headlines in the Daily News!
Oxolife in the radio
We are delighted to share the interview to our CEO Agnès Arbat on #Lideratges, Ariadna’s Belver Comin program, where … [Read more...] about Oxolife in the radio
At OXOLIFE we are celebrating!!
After a year since the start of our clinical trial and after the last milestone of end of recruitment, we want to share … [Read more...] about At OXOLIFE we are celebrating!!